nefazodone / Generic mfg. - LARVOL DELTA

MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review. (PubMed, PLoS One) - "This systematic review suggests current treatments for PTSD are associated with heterogeneous evidence and the majority do not demonstrate sustained effects. Results from MDMA-AT showed consistent improvements in CAPS, BDI and LOD."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Evaluation of the Effectiveness of l-Ergothioneine in Conjunction with Reactive Intermediates Derived from Model Pharmaceuticals. (PubMed, Chem Res Toxicol) - "These drugs included acetaminophen, diclofenac, carbamazepine, clozapine, nefazodone, raloxifene, tamoxifen, ticlopidine, troglitazone, and ethacrynic acid. Notably, our findings suggest that, in addition to scavenging reactive oxygen species, ET can also shield cells from reactive xenobiotic intermediates, similar to GSH. This research presents the first evidence of ET's role as a trapping agent for reactive drug intermediates."

Journal

Metabolism of m-CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects. (PubMed, Drug Metab Rev) - "This review aims to comprehensively explore the pharmacokinetics and pharmacodynamics of these compounds, with a specific focus on the forensic challenges posed by mCPPas a metabolite of antidepressants. The primary objective is to delineate the consumption patterns of these compounds in laboratory settings, making this review crucial for understanding the intricate nuances of these drugs in forensic contexts."

Journal • Review • Psychiatry • CYP3A4

Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database. (PubMed, PLoS One) - "This study provides a comprehensive assessment of drugs associated with DI-ALH through a rigorous analysis of the FAERS database using multiple signal detection methods. By identifying both well-known and previously underreported drugs, this study contributes to a more complete understanding of drug-induced liver injury. The findings have important implications for pharmacovigilance strategies and clinical risk assessment. However, limitations inherent in the FAERS database, such as underreporting and the potential for reporting bias, should be considered. Further clinical validation is warranted to confirm these associations."

Journal • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation • Liver Failure • Transplantation

Treatment for Depression in Patients Who Have Suffered from Early Life Stress. (PubMed, Psychiatr Danub) - "CBT was the most effective treatment for MDD with ELS. However, more research needs to be conducted to ascertain a proper hierarchy of treatments, particularly with combination treatments."

Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Computational Assessment of the Phytochemicals of Panax ginseng C.A. Meyer Against Dopamine Receptor D1 for Early Huntington's Disease Prophylactics. (PubMed, Cell Biochem Biophys) - "The molecular docking calculations against dopamine receptor D1 (PDB ID: 7X2F) involved in pathogenesis of early Huntington's disease gave the binding affinities (kcal/mol) of schizandrin (-10.530), ergosterol (-10.124), protopanaxadiol (-9.650), panaxydol (-9.399), diphenhydramine (-9.358), and panasenoside (-9.358). The values for native ligand (-7.748) and some selected drugs, Nefazodone (-9.880), Risperidone (-9.752), and Haloperidol (-9.712) were higher revealing weaker interactions...The sustained thermodynamic spontaneity of complex formation reaction augmented the inferences derived from spatial results. The phytochemicals from Panax ginseng could be used in the prophylactics of early Huntington's disease and recommendation is made for further evaluation by experimental work."

Journal • CNS Disorders • Huntington's Disease • Movement Disorders

Efficacy and dose-response relationships of antidepressants in the acute treatment of major depressive disorders: a systematic review and network meta-analysis. (PubMed, Chin Med J (Engl)) - "Although most antidepressants were more efficacious than placebo in treating MDD, no consistent dose-response relationship between any antidepressants was observed. For most antidepressants, the maximum efficacy was achieved at lower or middle prescribed doses, rather than at the upper limit."

Journal • Retrospective data • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Allosteric Inhibition and Pharmacochaperoning of the Serotonin Transporter by the Antidepressant Drugs Trazodone and Nefazodone. (PubMed, Mol Pharmacol) - "Here we show that - similar to the chemically related drug vilazodone - trazodone and nefazodone are allosteric ligands, which inhibit uptake by and transport-associated currents through SERT in a mixed-competitive and non-competitive manner, respectively. Trazodone and nefazodone rescued a folding-deficient variant of the serotonin transporter. This finding demonstrates that folding defects of mutated solute carrier-6 family members can also be corrected by allosteric ligands."

Journal • SLC6A4

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis. (PubMed, Ther Adv Drug Saf) - "Among the identified 42 antidepressants, nefazodone (n = 47, ROR = 7.79, IC = 2.91), fluvoxamine (n = 29, ROR = 4.69, IC = 2.20), and clomipramine (n = 24, ROR = 3.97, IC = 1.96) had the highest ROR for cholestatic injury; mianserin (n = 3, ROR = 21.46, IC = 3.99), nefazodone (n = 264, ROR = 18.67, IC = 3.84), and maprotiline (n = 15, ROR = 5.65, IC = 2.39) for hepatocellular injury; and nefazodone (n = 187, ROR = 12.71, IC = 0.48), clomipramine (n = 35, ROR = 2.07, IC = 0.26), and mirtazapine (n = 483, ROR = 1.96, IC = 0.94) for severe drug-related hepatic disorders...There are limited reports on the adverse reactions of relatively new antidepressant drugs, such as milnacipran, viloxazine, esketamine, and tianeptine, and those not approved by the Food and Drugs Administration, such as reboxetine and agomelatine...Duloxetine and clomipramine were associated with three DILI categories, except hepatic failure. The disproportionality analysis cannot conclude on a definite..."

Adverse events • Journal • CNS Disorders • Depression • Hepatology • Liver Failure • Mental Retardation • Psychiatry

Re-visiting the Association of Antidepressant Use and the Risk of Lung Cancer: A 10-year Retrospective Observational Cohort Study (APA 2024) - "Subgroup analysis in smokers showed decreased risk in the SSRI group (OR=0.72, 95% CI=0.57, 0.92); no risk difference in those taking SNRIs (OR=0.78, 95% CI=0.52, 1.17), bupropion (OR=0.64, 95% CI=0.37, 1.13), trazodone/nefazodone (OR=0.63, 95% CI=0.36, 1.12), or TCAs (OR=0.76, 95% CI=0.37, 1.58). Long-term antidepressant prescriptions are not associated with increased lung cancer risk in both non-smokers and smokers. Clinicians can reassure patients who have concerns about the correlation between antidepressants and lung cancer. We did not receive any funding for this study."

Observational data • Retrospective data • CNS Disorders • Lung Cancer • Mood Disorders • Oncology • Psychiatry • Solid Tumor

Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options. (PubMed, CNS Drugs) - "The main pharmacological approaches to treating CSBD have included opioid antagonists (naltrexone and nalmefene), selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine, and sertraline), mood stabilizers (topiramate), tricyclic antidepressants (clomipramine), serotonin antagonist and reuptake inhibitors (nefazodone), and N-acetylcysteine. However, to evaluate the efficacy of most of the drugs presented in this narrative review, data to date have only been available from case studies. Thus, empirical support is scant and generalizability of results is limited, highlighting the need for more research in this area."

Journal • Review • Behavior Disorders • CNS Disorders • Mental Retardation • Psychiatry

Pharmacological management of gambling disorder: an update of the literature. (PubMed, Expert Rev Neurother) - "The following classes of medications were considered: opioid-receptor antagonists (e.g. naltrexone and nalmefene), serotonin reuptake inhibitors (e.g. fluvoxamine, paroxetine, sertraline, escitalopram, and citalopram), glutamatergic agents (e.g. N-acetylcysteine (NAC), acamprosate, and memantine), mood stabilizers (e.g. topiramate, carbamazepine, lithium), and other medications (e.g. modafinil, nefazodone, olanzapine, haloperidol, tolcapone, and bupropion). The review highlights current gaps/limitations, including small sample sizes, limited diversity in participant demographics, the need for exploring different gambling subtypes and treatment responses, high placebo response rates, lack of longer-term longitudinal information, limited investigation of neurobiological correlates and co-occurring disorders, and the importance of implementation research. Further research is needed to address these gaps and explore additional medications, as well as interventions like..."

Journal • Review • Addiction (Opioid and Alcohol) • Tobacco Addiction

Inhibitory Actions of Antidepressants, Hypnotics, and Anxiolytics on Recombinant Human Acetylcholinesterase Activity. (PubMed, Biol Pharm Bull) - "At a concentration of 10 M, 22 antidepressants, 19 hypnotics, and 11 anxiolytics inhibited rhAChE activity by <20%, whereas nine antidepressants (clomipramine, amoxapine, setiptiline, nefazodone, paroxetine, sertraline, citalopram, escitalopram, and mirtazapine), two hypnotics (triazolam and brotizolam), and one anxiolytic (buspirone) inhibited rhAChE activity by ≥20%. Among these drugs, only nefazodone inhibited rhAChE activity within the blood concentration range achievable at clinical doses. Therefore, nefazodone may not only improve the depressive symptoms of BPSD through its antidepressant actions but also slow the progression of cognitive symptoms of AD through its AChE inhibitory actions."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Pain

Drugs for depressionr. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. (PubMed, Biochem Biophys Rep) - "Specific attention is given to psychotropic drugs such as bupropion, mirtazapine, and nefazodone, anti-inflammatory drugs like Celecoxib (COX-2 inhibitor), Etanercept, adalimumab, IL-4Ra antagonist, Anti-IL- 17A antibody (Ixekizumab) and lifestyle modifications including exercise, dietary changes, and sleep hygiene. These therapeutic solutions offer potential in treating depression by targeting metabolic conditions like insulin resistance and inflammatory pathways. The article further explains the significance of a nutrition and antioxidants-rich diet, emphasizing the role of omega-3 fatty acids, vitamin D, zinc, and polyphenols, to improve immunity and activate anti-inflammatory signaling pathways."

Journal • Review • CNS Disorders • Depression • Diabetes • Inflammation • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Psychiatry • Type 2 Diabetes Mellitus • IL4R

A gene expression profile-based approach to screen the occurrence and predisposed host characteristics of drug-induced liver injury: a case study of Psoralea corylifolia Linn. (PubMed, Front Chem) - "with definite hepatotoxicity, was selected as an experimental drug with highly similar molecular fingerprints to three idiosyncratic hepatotoxic drugs (nefazodone, trovafloxacin, and nimesulide) from the same DILI_PGS dataset. The animal experiment results found a single administration of psoralen could significantly induce liver injury in IS mice, while there was no obvious liver function change in IP mice by repeatedly administering the same dose of psoralen, and the potential mechanism of psoralen-induced liver injury in IS mice may be related to regulating the expression of the TNF-related pathway. In conclusion, this study constructed the DILI_PGS with high accuracy to predict the occurrence of DILI and preliminarily identified the characteristics of host factors inducing DILI."

Journal • Hepatology • Liver Failure • Oncology

Unveiling the therapeutic promise of natural products in alleviating drug-induced liver injury: Present advancements and future prospects. (PubMed, Phytother Res) - "From 1997 to 2016, eight drugs, including troglitazone, nefazodone, and lumiracoxib, were removed from the market due to their liver-damaging effects, which can cause diseases. To advance DILI management, it is crucial to conduct well-designed randomized clinical trials to evaluate natural products' efficacy and develop new molecules clinically. However, natural products are a promising solution for remedying drug-induced hepatotoxicity and lowering the risk of DILI."

Clinical • Journal • Review • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Respiratory Diseases • Tuberculosis

Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews. (PubMed, Curr Neuropharmacol) - "Some evidence may support the use of amitriptyline, nefazodone, paroxetine, and sertraline for improving sleep in patients with PTSD. Τhere was a meta-analytical trend indicating improvement of nightmares with fluoxetine, less insomnia with amitriptyline and more with brofaromine, as well as more somnolence with paroxe- tine vs. placebo, respectively...Evidence is insufficient to draw safe conclusions. More and better-designed RCTs, with consistent reporting of sleep-related outcomes, are needed."

Journal • CNS Disorders • Insomnia • Mood Disorders • Post-traumatic Stress Disorder • Sleep Disorder

Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Polypharmacy based on tacrolimus or cyclosporine needs vigilant therapeutic drug monitoring due to the cytochrome P450 enzymes associated with biochemical variables in metabolic pathways. Further attention to polypharmacy should be given to circulate drugs that could hide pharmacokinetics interactions associated with infections, malignancies, chronic kidney disease, and rejection after organ transplantation."

Journal • Chronic Kidney Disease • Infectious Disease • Nephrology • Oncology • Renal Disease • Solid Organ Transplantation • Transplantation

Global xenobiotic profiling of rat plasma using untargeted metabolomics and background subtraction-based approaches: Method evaluation and comparison. (PubMed, Curr Drug Metab) - "Metabolomics methods are capable of GXP and measuring alternations of endogenous metabolites in a group of biological samples, while PATBS is more suited for sensitive GXP of a single biological sample. A combination of metabolomics and PATBS approaches can generate better results in the untargeted profiling of unknown xenobiotics."

Journal • Preclinical

FKBP5 blockade may provide a new horizon for the treatment of stress-associated disorders; an in-silico study. (PubMed, Epilepsia Open) - "While the current in-silico repurposing study could identify potential drugs (that are already approved and are widely available) for designing clinical trials in patients with stress-associated disorders (e.g., FS), any future clinical trial should consider the pharmacological profile of the desired drug and also the characteristics and comorbidities of the patients in order to foster a success."

Journal • Anesthesia • CNS Disorders • Epilepsy • Pain • FKBP5

New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. (PubMed, Expert Opin Pharmacother) - "Among the SSRIs not labeled for SAD, citalopram showed the most promising results. Quetiapine, levetiracetam, and other antidepressants/serotonergic agents, such as fluoxetine, duloxetine, monoamine oxidase inhibitors, tricyclics, mirtazapine, atomoxetine, nefazodone, vilazodone, and buspirone, presented negative, limited, or contrasting results. Data on anticonvulsants, olanzapine, tiagabine, and ketamine were positive, but preliminary. The risk/benefit ratio must be considered in the prescription of unlabeled compounds; treatment with pregabalin may be associated with somnolence and dizziness. Future research may contribute to the identification of targeted molecules for the treatment of this disorder."

Journal • CNS Disorders • Mood Disorders • Psychiatry • Social Anxiety Disorder

Preliminary study to classify mechanisms of mitochondrial toxicity by in vitro metabolomics and bioinformatics. (PubMed, Toxicol Appl Pharmacol) - "Our results provided new insights into classifying mechanisms of mitochondrial toxicity by in vitro metabolomics."

Journal • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Liver Failure • Renal Cell Carcinoma • Solid Tumor

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. (PubMed, Brain Sci) - "There is a direct association between craving and cocaine use, underscoring craving as an important treatment target for promoting abstinence among persons with cocaine use disorder. Clonidine, fenfluramine and m-CPP showed to be promising medications for cocaine craving in the short-term treatment, and amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone in the long-term treatment."

Clinical • Journal • Review • Addiction (Opioid and Alcohol) • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. (PubMed, Mol Psychiatry) - "The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, vilazodone, and vortioxetine) and a placebo. Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD."

Retrospective data • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry